The role of insulin in type 2 diabetes management and challenges to optimal initiation Type 2 diabetes mellitus (T2DM) is a progressive disease, and many patients eventually require intensification of therapy from oral anti-diabetes agents. Basal insulin therapy is a cornerstone of T2DM management for patients who do not achieve glycaemic control following intensification of oral-therapy regimens. 1, 2 Insulin is an effective option for those with long-standing diabetes, and may be considered as a direct addition to metformin in patients with uncontrolled hyperglycaemia. [1] [2] [3] [4] [5] [6] However, there are psychological and behavioural considerations associated with insulin treatment -from both the perspective of the patient and of the physician -that may result in basal insulin therapy being frequently and inappropriately delayed. 7 Patients often see insulin therapy as inconvenient, potentially painful, as a treatment of 'last resort' and an indication of failure to manage their disease. 2, 8 Physicians may be reticent to initiate the 'final' option of the recommended stepwise treatment algorithms, and typically share concerns with their patients over weight gain, burden of injections, and an increased risk of hypoglycaemia. 1, 2, 8, 9 Indeed, a recent large-scale (n=40,627) real-world study found that the majority of patients did not achieve a target glycated haemoglobin (HbA 1c ) of ≤7% in the first 3 months or after 2 years, following initiation of basal insulin treatment; the authors noted the role that treatment inertia might play in avoidable, inadequate glycaemic control. 10 After initiation of basal insulin, delays in escalating titration (i.e.
clinical inertia) have also been observed, contributing to suboptimal glycaemic control. 11, 12 Overcoming treatment inertia and appropriate insulin initiation
Patient concerns should be managed through education, 8, 13 which might include the benefits of glycaemic control, both in the short term and in terms of reduced complications in the longer term, and how appropriate insulin initiation using a personalised treatment approach can help achieve this.
EUROPEAN ENDOCRINOLOGY
Physicians should consider that stepwise management algorithms typically wait for a treatment to be ineffective before escalation to, or addition of, another agent. This 'wait for failure' approach often means that patients may not be initiated on insulin therapy for relatively long periods of time, 2, 14, 15 although current treatment recommendations from the American Diabetes Association and the European Association for the Study of Diabetes highlight that target achievement should be evaluated 3 months after a change of treatment has been made. 1, 2 Suboptimal glycaemic control arising from treatment inertia has been observed in patients receiving oral anti-diabetes drugs (OADs), with notable delays in treatment escalation and a median of over 7 years before initiation of insulin treatment. 15 In patients receiving three OADs, the probability of adding an OAD or initiation of insulin was 5.7% after 1 year (no patients received a fourth OAD), and mean HbA 1c was 9.7% at the point of intensification to insulin. 15 However, there exists compelling evidence to support a more active and target-driven approach, with long-term studies demonstrating the benefits of early target-driven treatment of hyperglycaemia in terms of reducing micro-and macro-vascular complications (Table 1) . 16, 17 Reductions in risk of microvascular disease, myocardial infarction and death achieved with a median of 10 years of intensive glycaemic control 16 were maintained during 10 years of post-trial follow-up. 17 Treat-to-target management can be supported with a personalised treatment approach, using timely escalation through step-wise guidelines to achieve tight glycaemic control and reduce unnecessary glycaemic burden resulting from delayed or suboptimal intervention.
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Era of the second-generation basal insulin analogue
In recent years, significant advances have been made in basal insulin therapy. The second generation of basal insulin analogues offers compelling therapeutic benefits over first-generation insulin therapies, which may help physicians and patients overcome some of the barriers to initiation and intensification of insulin treatment. [18] [19] [20] [21] [22] [23] Second-generation basal insulin analogues (insulin glargine 300 U/ mL [Gla-300; Sanofi, Paris, France] and insulin degludec [IDeg; Novo Nordisk, Bagsvaerd, Denmark]) have demonstrated similar efficacy in reducing HbA 1c to first-generation insulin therapy (e.g. insulin glargine 100 U/mL [Gla-100; Sanofi]). 18 However, the newer agents have longer and more stable pharmacokinetic (PK) and pharmacodynamic (PD) profiles than first-generation treatments.
19-23 Gla-300 is associated with low within-day variability and high reproducibility (low betweenday variability) in insulin exposure, 19,24 with predictable and stable glycaemic control well beyond 24 hours. 25 Similarly, IDeg has demonstrated activity for up to 42 hours with four times lower dayto-day within-patient variability in glucose reduction compared with Gla-100. 20 A comparison of the steady state PK/PD profiles of Gla-300 and IDeg revealed that Gla-300 provided 20% less within-day fluctuation of metabolic activity than IDeg over 24 hours at a dose of 0.4 U/kg/day (Figure 1 ).
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These advances have translated into the clinically meaningful benefit of providing similar glycaemic control to Gla-100, but with an ultra-long duration (>24-hour coverage), a more stable PK profile (resulting in reduced glycaemic variability), and greater injection time flexibility. These factors make second-generation basal insulin analogues suitable for once-daily treatment. [19] [20] [21] [22] [23] In addition to effectively reducing HbA 1c , the second-generation basal insulin analogues are associated with a lower risk of hypoglycaemia (both nocturnal hypoglycaemia and also, for Gla-300, all-day hypoglycaemia) compared with Gla-100 ( Figure 2) . 18, 27, 28 For Gla-300, the benefit of lower incidence of hypoglycaemia is especially pronounced in the titration period.
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Concluding remarks
The second-generation basal insulin analogues provide physicians with new treatment options for achieving targeted glycaemic control.
While providing similar efficacy in lowering HbA 1c to first-generation insulin analogues, the newer insulin treatment options provide additional clinical benefits, including a more stable, ultra-long duration of action that enables once-daily administration with flexibility in daily injection time, together with a lower risk of hypoglycaemia. ❒ (less intra-day variation), together with a lower risk of hypoglycaemia, in patients with type 2 diabetes mellitus (T2DM). [1] [2] [3] [4] [5] As a result, clinicians now have insulin treatment options that provide glycaemic control with the benefit of a stable, ultra-long duration of action that allows once-daily administration with flexibility in daily injection time. However, while the available evidence demonstrates that Gla-300 and IDeg provide similar clinical benefits to first-generation basal insulin analogues (albeit via different mechanisms of action), [5] [6] [7] no direct comparison between the second-generation basal insulin analogues has been presented to date.
Emerging data from the 11 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Data from three studies of second-generation basal insulin analogues were presented at ATTD (Vienna, Austria) in February 2018. Real-world evidence from the DELIVER-D study 8 was validated by a second realworld study, LIGHTNING, 9 which used a similar methodology applied to a larger source dataset of electronic medical records. In addition to the real-world studies, the BRIGHT study provides the first randomised controlled trial (RCT) evidence from a head-to-head comparison of second-generation basal insulin analogues. 10 The most recent data from each of these three studies (DELIVER-D, LIGHTNING, BRIGHT) were presented at the ATTD 2018 meeting and are reviewed here.
Assessing comparative real-world findings in patients switching from first-to secondgeneration basal insulin analogues DELIVER-D
Previously published data from the EDITION and BEGIN clinical trials and subsequent meta-analyses have demonstrated consistent efficacy and improved safety profiles for second-generation basal insulin analogues (Gla-300 in EDITION and IDeg in BEGIN), compared with insulin glargine 100 U/mL (Gla-100). [5] [6] [7] However, the extent to which these findings from strictly controlled RCT settings are applicable to real-life practice has yet to be examined. In these initial trials, patients with hypoglycaemia were often excluded. [5] [6] [7] In addition, no direct comparisons between Gla-300 and IDeg have been presented to date.
DELIVER-D was a retrospective, observational study assessing safety and efficacy outcomes from electronic medical records in patients in the US switching from first-generation Gla-100 to either Gla-300 or IDeg.
Head-to-head differences between the two second-generation basal insulin analogues were investigated. March 2015 to 31st December 2016) and who had at least one Gla-100 prescription within 6 months before the index date (baseline period), but who had not received any other basal insulin prescriptions during this period. In order to be included in the study, patients were required to have electronic medical records for at least 12 months prior to, and at least 6 months following the index date, and to have had at least one glycated haemoglobin (HbA 1c ) measurement during the 6-month baseline period. 8 Patients who switched from Gla-100 to Gla-300 or IDeg were matched in a 1:1 ratio using a propensity score based on: baseline demographics In the subgroup, the endpoints examined were HbA 1c reduction from baseline (closest to index date) at follow-up (latest available value during the follow-up period), and the proportion of patients attaining target HbA 1c . Until RCT data are available to support head-to-head comparisons, these data provide valuable insights into real-world outcomes and demonstrate the improved efficacy and safety profiles of modern second-generation basal insulin analogues in routine clinical practice.
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LIGHTNING
The LIGHTNING study assessed real-world efficacy and safety outcomes in patients with T2DM switching to first-(Gla-100 or insulin detemir [IDet]) or second-generation (Gla-300 or IDeg) basal insulin analogues. Preliminary results of an analysis of Humedica electronic health records -a database capturing data from over 5 million people with diabetes across more than 50 US healthcare systems, 700 hospitals and 7,000 clinics -from 1st April 2015 to 31st December 2016 -are presented here. 9 The dataset included 779,813 people with T2DM receiving basal insulin analogues. A total of 130,155 basal insulin analogue treatments complied with the study inclusion criteria (Figure 2) , representing patients either initiating a new basal insulin or switching between basal insulins. Patients were excluded from the study if they had a likely predominant diagnosis of type 1 diabetes, or if they had more than 10 basal insulin switches within the study window (as such cases would likely represent unusual clinical behaviour). 9 Data presented here focus only on findings in patients switching between basal insulin treatment options.
The study approached its assessment using an analysis unit of 'patient Switching from any basal insulin, patients who switched to Gla-300 had a significantly lower incidence of severe hypoglycaemia versus patients switched to the first-generation basal insulin analogues Gla-100 and IDet (p=0.009 and p=0.002, respectively). In the direct comparison between second-generation basal insulins, IDeg and Gla-300 provided similar reductions (p=0.370) in the rate of severe hypoglycaemia (Figure 3) . 9 Overall, results of the analysis showed that there was a similar reduction in HbA 1c for patients switching to Gla-100, IDet and Gla-300, and similarly there was no significant difference between the second-generation treatments (Gla-300 and IDeg; p=0.591; Figure 4 ). The first randomised, controlled head-to-head comparison of second-generation basal insulin analogues BRIGHT Recent real-world observations have shown that switching from Gla-100 to either Gla-300 or IDeg resulted in similar improvements in terms of hypoglycaemia risk during the whole follow-up period. Rates of severe hypoglycaemia were similar for the second-generation treatments and significantly lower than first-generation basal insulins, without compromising efficacy in HbA 1c reduction. 8, 9 However, despite the valuable insights obtained from real-world assessments, PK and PD data, and meta-analyses, there has been an absence of RCT head-to-head comparisons of second-generation basal insulin analogues. Such data from randomised controlled studies could help to inform and support optimal treatment selection in T2DM.
The BRIGHT study was a phase IV, 24-week, multinational, multicentre, open-label, two-arm, parallel-group trial (NCT02738151), including insulin-naïve adults with T2DM inadequately controlled with oral antihyperglycaemic drugs, with or without a glucagon-like peptide-1 receptor agonist ( Figure 5) . 10 Patients were randomised 1:1 to receive Gla-300 (0.2 U/kg) or IDeg (10 U), administered once-daily using similar treat-totarget titration protocols.
The primary endpoint was HbA 1c change from baseline to Week 24; both the non-inferiority and then superiority of Gla-300 versus IDeg were assessed. Secondary endpoints included the incidence and event rates of hypoglycaemia, blood glucose level changes, variability of pre-breakfast glucose and adverse events. 10 The study also included patient-reported outcomes as assessed by the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Hypoglycaemia Attitudes and Behaviour Scale (HABS). 11, 12 At ATTD 2018, study demographics were presented for the BRIGHT study and are summarised here. Overall, 929 participants from 16 countries were randomised to Gla-300 or IDeg and 94% of participants completed the 24-week treatment period ( Figure 6) . 10 Baseline characteristics were well-balanced between the two treatment cohorts, with an average age of 60 years, a baseline HbA 1c of 8.6-8.7% and around half of patients having previously used more than two non-insulin glycaemic control drugs ( Table 1) . Meneghini et al., 2018. 9 Gla-300 Gla-100 = insulin glargine 100 U/mL; Gla-300 = insulin glargine 300 safety concerns were noted ( Table 2) . A similar proportion of patients in each treatment arm experienced treatment-related adverse events, with few serious events (less than 5% in each arm) and only around 1% of patients discontinuing treatment because of adverse effects. 10 We await with interest further details on results from the BRIGHT study, comparing second-generation insulins in a head-to-head context.
Discussion
With the availability of second-generation basal insulin analogues, clinicians now have ultra-long acting, efficacious treatment options with a low associated risk of hypoglycaemia.
Selection of a treatment for the personalised management of diabetes should be supported by data in relevant patient populations: here we have discussed both real-world data and clinical observations to supplement existing evidence from phase III RCTs and meta-analyses for Gla-300.
DELIVER-D demonstrated that switching from Gla-100 to Gla-300 or IDeg provides similar glucose-lowering efficacy and reductions in hypoglycaemia risk between the second-generation insulins. LIGHTNING supported these findings, reporting a similar incidence of severe hypoglycaemia for Gla-300 and IDeg, but lower than first-generation basal insulins, while retaining efficacy in HbA 1c reduction. Reproduced with permission from: Cheng et al., 2018. 10 Early demographic data from the head-to-head BRIGHT study show that it is well positioned, in terms of patient selection, randomisation and appropriate titration, to deliver meaningful insights into T2DM treatment selection when further data are released.
Together, data from both RCTs and real-world studies provide physicians with robust evidence for the clinical benefits of second-generation basal insulin analogues and support informed decisions when initiating and intensifying basal insulin therapy. ❒
